Ondine Biomedical Inc. announces the appointment of Kwong Choo as Interim Chief Financial Officer, following the resignation of previous CFO J. P. Errico. Mr. Choo, CPA, CIMA, brings more than15 years of experience in international public companies on NASDAQ, the Toronto Stock Exchange, and the TSX Venture Exchange, as well as with a number of private biotechnology and pharmaceutical companies. Mr. Choo has been working with Ondine since 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.875 GBX | 0.00% | -12.96% | -32.86% |
Apr. 24 | EARNINGS AND TRADING: Nichols trading in line; Ondine revenue doubles | AN |
Apr. 22 | Ondine Biomedical celebrates use of Steriwave in Australian hospital | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.86% | 16.59M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- OBI Stock
- News Ondine Biomedical Inc.
- Ondine Biomedical Inc. Announces Chief Financial Officer Changes